QIAGEN Gains FDA Clearance for QIAstat-Dx Bloodstream Panel
GERMANTOWN, Md. and VENLO, Netherlands — September 28, 2026 QIAGEN N.V. announced that the U.S. Food and Drug Administration...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
GERMANTOWN, Md. and VENLO, Netherlands — September 28, 2026 QIAGEN N.V. announced that the U.S. Food and Drug Administration...
Germantown, Maryland, and Venlo, Netherlands, August, 10, 2026 QIAGEN has received U.S. Food and Drug Administration (FDA) clearance for...
LOS ANGELES, May 7, 2026 Armata Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
